LATEST NEWS
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in…
VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://oncologytube.com/tag/moasc-2024-oncology-summit/ featuring presentations from @KarenReckampMD @jtmoyers @Dr_RShatsky @arafflemd Heinz-Josef Lenz @akhtari_mojtaba @DrLizBrem @UCIrvineHealth @CancerCenter @CityofHopeCME…
Check out the incredible young investigators from @cityofhope who presented their work at #MOASC24! A huge thanks to @MOASC_Office, our state society, & @oncologytube for offering them an opportunity to shine! @SalvadorjcMD @AlexisLevee @NazliDizman @NickSalgia…
Oncology Conference Videos
Oncology News
Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved…
Where do you see the greatest utility of ctDNA testing in patients with solid tumors?
In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual…
NRG Oncology/NSABP B-51/RTOG1304 Primary Outcomes – Terry Mamounas, MD [SABCS 2023]
By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with…
In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina,…
Managing High-Risk Hematologic Malignancies in the Community [ASH 2023]
Dipti Patel-Donnelly, a medical oncologist at the Virginia Cancer Specialists, leads a study titled “How…
Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 Practice patterns for sequential use of antibody-drug conjugate after antibody-drug 1
By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist…
OLAnzaPiNE-3: Low-Dose vs Standard-Dose Olanzapine in Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy in Solid Tumor
By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…